|Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma|
Craig Moskowitz, MD
|Release Date: May 19, 2017|
Expiration Date: May 19, 2018
|The approval of nivolumab in May of 2016 for patients with classical Hodgkin lymphoma (HL) that has relapsed or progressed after autologous stem cell transplant and post-transplantation brentuximab vedotin, represented the first checkpoint inhibitor in HL. The unique features of checkpoint inhibitors, including immune-mediated adverse events and the possibility of non-traditional response patterns, may create a challenge in using these agents in practice. In this activity, Dr. Moskowitz will discuss the clinical profiles of recently approved immunotherapeutic agents, as they relate to HL, focusing on practical strategies for treatment and management of patients in practice, as well as on the safety and efficacy profiles of each.|
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
|Begin, Earn CreditView Only, No Credit|